Successful management of intractable nausea with ondansetron: A case study

Journal of Palliative Care

Volumn 12, Issue 2, 1996, Pages 47-50

  Pereira, Jose ^a   Bruera, Eduardo ^a  

^a Edmonton General Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ONDANSETRON;

AGED; ARTICLE; CASE REPORT; DRUG ADMINISTRATION; FEMALE; HUMAN; NAUSEA; PALLIATIVE THERAPY;

AGED; ANTIEMETICS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NAUSEA; ONDANSETRON; PALLIATIVE CARE;

EID: 0030160120     PISSN: 08258597     EISSN: None     Source Type: Journal    
DOI: 10.1177/082585979601200210     Document Type: Article

References (16)

1. Fainsinger R, Bruera E, Miller MJ, Hanson J, MacEachern T. Symptom Control during the last week of life on a palliative care unit. J Palliat Care 1991; 7(1): 5-11.
2. Simon A. Nausea and vomiting. In: D Doyle, G Hanks, N MacDonald, (Eds), Oxford Textbook of Palliative Medicine. London: Oxford Medical Publications, 1993; pp. 282-290.
3. Bruera E, Catz Z, Hooper R, Lentle B, MacDonald RN. Chronic nausea and anorexia in patients with advanced cancer: a possible role for autonomic dysfunction. J Pain Sympt Manag 1987; 2(1): 19-21.
4. Hagen N, Foley K, Carbone D, Portenoy R, Inturrisi C. Chronic nausea and morphine-6-glucuronide. J Pain Sympt Manag 1991; 6(3): 125-128.
5. Bruera E, Seifert L, Watanabe S, Babul N, Darke A, Harsanyi Z, Suarez-Almazor M. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regime. J Pain Symptom Manag (in press).
6. Bruera E, Macmillan K, Hanson J, MacDonald RN. The Edmonton injector: a simple device for patient-controlled subcutaneous analgesia. Pain 1991; 44: 167-169.
7. Fainsinger RL, MacEachern T, Miller MJ, Bruera E, Spachynski K, Kuehn N, Hanson. The use of hypodermoclysis (HDC) for rehydration in terminally ill cancer patients. J Pain Sympt Manag 1994; 9(5): 298-302.
8. Bruera E, Brenneis C, Michaud M, MacDonald N. Continuous subcutaneous infusion of metoclopramide using a portable disposable pump. Clin Invest Med 1986; 9#R-768: A-123.
9. Peroutka SJ, Snyder SH. Anti-emetics: Neurotransmitter receptor binding predicts therapeutic actions. Lancet 1982; 1: 658-659.
10. Hesketh P. Treatment of chemotherapy-induced emesis in the 1990s: impact of the receptor antagonists. Support Care Cancer 1994; 2: 286-292.
11. Markham A, Sorkin L. Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993; 45(6): 931-952.
12. Tonato M, Roila F, Del Favero A, Ballatori E. Antiemetics in cancer chemotherapy: historical perspective and current state of the art. Support Care Cancer 1994; 2: 150-160.
13. Cole R, Robinson F, Harvey L, Trethowank, Murdoch V. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. J Pain Sympt Manag 1994; 9(1): 48-50.
14. Evans JE. Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron. Med J Austr 1993; 159: 125-127.
15. Wynn R, Essien E, Thut P. The effects of different antiemetic agents on morphine-induced emesis in ferrets. European J Pharm 1993; 241: 47-54.
16. de Stoutz N, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Sympt Manag 1995; 10(5): 378-384.